Zydus Lifesciences Limited (NSE:ZYDUSLIFE)
India
· Delayed Price · Currency is INR | Market Cap | 981.08B |
| Revenue (ttm) | 236.08B |
| Net Income (ttm) | 45.72B |
| Shares Out | 1.01B |
| EPS (ttm) | 45.44 |
| PE Ratio | 21.46 |
| Forward PE | 22.13 |
| Dividend | 11.00 (1.13%) |
| Ex-Dividend Date | Jul 25, 2025 |
| Volume | 2,575,036 |
| Average Volume | 1,027,615 |
| Open | 996.20 |
| Previous Close | 1,019.25 |
| Day's Range | 972.70 - 1,010.00 |
| 52-Week Range | 795.00 - 1,088.85 |
| Beta | 0.47 |
| RSI | 36.36 |
| Earnings Date | Nov 14, 2025 |
About Zydus Lifesciences
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, consumer wellness and animal health products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. The company also provides a pi... [Read more]
Financial Performance
In 2024, Zydus Lifesciences's revenue was 232.42 billion, an increase of 18.90% compared to the previous year's 195.47 billion. Earnings were 45.26 billion, an increase of 17.26%.
Financial StatementsNews
Zydus Lifesciences’ ZyVet launches first veterinary-approved generic of Furosemide tablets
Zydus Lifesciences Ltd., a global healthcare company known for its innovation-led approach, has announced a major milestone in veterinary medicine through its U.S. subsidiary. ZyVet®, the dedicated an...
Zydus Lifesciences’ ZyVet launches first FDA-approved generic treatment for canine urinary incontinence
ZyVet® Animal Health, the animal health division of Zydus Lifesciences, has launched its first FDA-approved generic version of phenylpropanolamine hydrochloride tablets, a trusted treatment for managi...
Basal Cell Neoplasms Clinical Trial Pipeline Accelerates as 22+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
New York, USA, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Basal Cell Neoplasms Clinical Trial Pipeline Accelerates as 22+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight Basal Cell N...
Zydus Lifesciences shares jump over 2% as subsidiary enters into licensing and supply agreement with Synthon BV
Zydus Lifesciences shares rose over 2% in early morning trade following a major announcement by the company regarding its subsidiary’s strategic move in the US pharmaceutical market. The subsidiary ha...
Top stocks to watch today, September 5: HDFC Life, HCLTech, Zydus Lifesciences, Bharat Forge and more
Several companies are expected to remain in focus today, following regulatory updates and corporate developments. Here’s a look at the top stocks to watch on Friday, September 5, 2025. Top Stocks To W...
Stocks to watch today, Sept 5: Sterlite Tech, JB Chemicals, Bharat Forge, Zydus Lifesciences, Varun Beverages in focus
Indian markets are expected to remain stock-specific on Friday, September 5, 2025, as a series of corporate announcements and strategic developments put several companies in focus. Here are the major ...
ICMR issues licences to industry partners for 9 breakthrough techs
The Indian Council for Medical Research (ICMR) has licensed nine groundbreaking health technologies to industry partners, including a multistage malaria vaccine licensed to multiple companies like Ind...
Zydus enters exclusive licensing deal with Synthon for Ozanimod capsules in US market
Zydus Lifesciences Ltd has announced that its wholly owned subsidiary has entered into an exclusive licensing and supply agreement with Netherlands-based Synthon BV for Ozanimod Capsules, the generic ...
Zydus Lifesciences launches VaxiFlu trivalent influenza vaccine for flu protection in India
Zydus Lifesciences Ltd., a global innovation-driven healthcare company, has officially launched its trivalent influenza vaccine, VaxiFlu™, marking the first time this vaccine is introduced in India. T...
Zydus Therapeutics Reports Positive Topline Results from EPICS-III Phase 2(b)/3 Trial of Saroglitazar Magnesium in Patients with Primary Biliary Cholangitis
Zydus Therapeutics, a wholly owned subsidiary of Zydus Lifesciences Ltd., a global innovation led healthcare company, today announced positive topline results from the pivotal EPICS-III Phase 2(b)/3 c...
Zydus Therapeutics reports positive Phase 2b/3 trial results for Saroglitazar in Primary Biliary Cholangitis
Zydus Therapeutics, the U.S.-based innovation arm of Zydus Lifesciences Ltd., announced on August 29, 2025, that its investigational therapy Saroglitazar Magnesium delivered positive topline results i...
Stocks to watch on brokerages’ radar today, August 13: Minda Corp, Apollo Hospitals, Alkem Labs, Nykaa, Zydus Lifesciences, HAL, ONGC, NHPC, Honasa, Paytm
Brokerages have issued fresh calls and revised targets for several key companies, with updates spanning the auto ancillary, healthcare, pharma, defence, energy, and consumer sectors. Minda Corp share:...
Zydus Lifesciences Q1 net profit rises 3% to Rs 1,467 crore
India Business News: Zydus Lifesciences on Tuesday said its consolidated net profit increased 3 per cent year-on-year to Rs 1,467 crore for the first quarter ended June 30.
Zydus Lifesciences Q1 Results: Revenue rises 5.9% YoY to Rs 6,573.7 crore, Net profit up 3.7% YoY
Zydus Lifesciences reported a 5.9% year-on-year (YoY) increase in revenue from operations at Rs 6,573.7 crore for the quarter ended June 30, 2025, compared to Rs 6,207 crore in the same quarter last y...
Top Q1 results today, August 12: HAL, ONGC, Hindalco Industries, Zydus Lifesciences, Bharat Dynamics and more to announce earnings
As the June quarter results season approaches its final days, a significant number of prominent Indian companies are gearing up to announce their financial performance. Tuesday, August 12, 2025, will ...
Zydus Lifesciences gets USFDA final approval for Diltiazem Hydrochloride tablets
Zydus Lifesciences Limited, along with its subsidiaries and affiliates (collectively referred to as “Zydus”), has secured final approval from the United States Food and Drug Administration (USFDA) for...
Zydus Lifesciences gets USFDA nod for Prucalopride tablets, 1 mg and 2 mg
Zydus Lifesciences Limited has received final approval from the US Food and Drug Administration (USFDA) to market Prucalopride Tablets, 1 mg and 2 mg (reference listed drug: Motegrity®). The tablets a...
Zydus Lifesciences gets tentative approval from USFDA for Ibrutinib tablets
Zydus Lifesciences has received tentative approval from the USFDA to market Ibrutinib tablets in the 140 mg, 280 mg, and 420 mg strengths in the U.S. market. The drug is a generic version of Imbruvica...
Zydus Lifesciences secures USFDA approval for Celecoxib Capsules
Zydus Lifesciences has received final approval from the US Food and Drug Administration (USFDA) to market Celecoxib Capsules in the U.S. market. The approval covers four dosage strengths — 50 mg, 100 ...
Jefferies maintains buy on Zydus Lifesciences, sees 15.5% upside on resilient FY26 growth outlook
Jefferies has reaffirmed its Buy rating on Zydus Lifesciences with a target price of ₹1,150, implying a potential upside of 15.5% from the current market price of ₹996.00. The brokerage expressed conf...
Zydus completes USFDA inspection at oncology plant with two minor observations, none related to data integrity
Zydus Lifesciences Ltd has announced the successful conclusion of a Good Manufacturing Practices (GMP) follow-up inspection by the United States Food and Drug Administration (USFDA) at its oncology in...
Stocks to watch on June 12: Zydus Life, Adani Group, Tanla Platforms, HUL, Nazara Tech, MCX in focus
Markets will track a range of corporate developments and sectoral updates on Wednesday, June 12. Here’s a look at the key stocks in focus: Positive Triggers Zydus Lifesciences: Received Establishment ...
Zydus receives USFDA EIR for Ankleshwar API facility with ‘No Action Indicated’ status
Zydus Lifesciences Limited announced on Wednesday that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its API manufacturing f...
Zydus receives EIR with VAI classification from USFDA for Dabhasa API facility
Zydus Lifesciences has received the Establishment Inspection Report (EIR) from the USFDA for its API manufacturing facility at Dabhasa, near Vadodara. The inspection, conducted from April 21 to April ...
Top stocks to buy today: Stock recommendations for June 5, 2025
Top stock market recommendations: Aakash K Hindocha suggests a cautious outlook for Nifty and Bank Nifty, anticipating potential declines to 24300/24100 and 54700/54500, respectively. He recommends bu...